Jean-Pierre Valentin

Jean-Pierre Valentin

Auto-generated profile, based on publicly available information

Jean-Pierre Valentin


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2023 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
FPF. Pognan
F. Pognan
MBMario Beilmann
Mario Beilmann
HBHarrie C. M. Boonen
Harrie C. M. Boonen
ACAndreas Czich
Andreas Czich
GDGordon Dear
Gordon Dear
PNPeter Newham
Peter Newham

21 May 2024 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
RBRichard J. Brennan
Richard J. Brennan
SJStephen Jenkinson
Stephen Jenkinson
ABAndrew Brown
Andrew Brown
ADAnnie DELAUNOIS
Annie DELAUNOIS
BDBérengère Dumotier
Bérengère Dumotier
JVJean-Pierre Valentin
Jean-Pierre Valentin

1 September 2018 in Journal of Pharmacological and Toxicological Methods
Verified
Journal Article
Closed access
JVJean-Pierre Valentin
Jean-Pierre Valentin
JGJean-Michel Guillon
Jean-Michel Guillon
SJStephen Jenkinson
Stephen Jenkinson
VKVivek Kadambi
Vivek Kadambi
PRPeri Ravikumar
Peri Ravikumar
DADuncan Armstrong
Duncan Armstrong

24 February 2023 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
JVJean-Pierre Valentin
Jean-Pierre Valentin
DLDerek Leishman
Derek Leishman

11 December 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
KCKhuram W. Chaudhary
Khuram W. Chaudhary
CCColleen E. Clancy
Colleen E. Clancy
PYPei‐Chi Yang
Pei‐Chi Yang
JPJennifer B. Pierson
Jennifer B. Pierson
AGAlan L. Goldin
Alan L. Goldin
MPMichael K. Pugsley
Michael K. Pugsley
The human voltage‐gated sodium channel Nav1.5 (hNav1.5/SCN5A) plays a critical role in the initiation and propagation of action potentials in cardiac myocytes, and its modulation by various drugs has significant implications for cardiac safety. Drug‐dependent block of Nav1.5 current (INa) can lead to significant alterations in cardiac electrophysiology, potentially resulting in conduction slowing and an increased risk of proarrhythmic events. This review aims to provide a comprehensive overview of the mechanisms by which various pharmacological agents interact with Nav1.5, focusing on the molecular determinants of drug binding and the resultant electrophysiological effects. We discuss the structural features of Nav1.5 that influence drug affinity and specificity. Special attention is given to the concept of state‐dependent block, where drug binding is influenced by the conformational state of the channel, and its relevance to therapeutic efficacy and safety. The review also examines the clinical implications of INa block, highlighting case studies of drugs that have been associated with adverse cardiac events, and how the Vaughan‐Williams Classification system has been employed to qualify “unsafe” sodium channel block. Furthermore, we explore the methodologies currently used to assess INa block in nonclinical and clinical settings, with the hope of providing a weight of evidence approach including in silico modeling, in vitro electrophysiological assays and in vivo cardiac safety studies for mitigating proarrhythmic risk early in drug discovery. This review underscores the importance of understanding Nav1.5 pharmacology in the context of drug development and cardiac risk assessment.

6 March 2025 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
JVJean-Pierre Valentin
Jean-Pierre Valentin
DLDerek Leishman
Derek Leishman